CAS 873054-44-5: Ivacaftor
Description:Ivacaftor is a pharmaceutical compound primarily used in the treatment of cystic fibrosis, particularly in patients with specific mutations in the CFTR gene. It functions as a CFTR potentiator, enhancing the function of the defective protein produced by the CFTR gene. Ivacaftor is characterized by its molecular formula, which includes carbon, hydrogen, nitrogen, and oxygen atoms, contributing to its complex structure. The substance is typically administered orally and is known for its relatively high bioavailability. It exhibits a moderate solubility in water and is often formulated in tablet form for ease of use. Ivacaftor's mechanism of action involves binding to the CFTR protein, facilitating the opening of the chloride channels, which helps to improve ion transport and mucus clearance in the lungs. The drug has been shown to significantly improve lung function and reduce pulmonary exacerbations in patients with the appropriate genetic profile. As with any medication, it is essential to monitor for potential side effects and drug interactions during treatment.
Formula:C24H28N2O3
InChI:InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)
InChI key:InChIKey=PURKAOJPTOLRMP-UHFFFAOYSA-N
SMILES:O=C(NC1=CC(O)=C(C=C1C(C)(C)C)C(C)(C)C)C2=CNC=3C=CC=CC3C2=O
- Synonyms:
- 3-Quinolinecarboxamide, N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-
- Ivacaftor
- Kalydeco
- N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide
- N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
- N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide
- N-[2,4-Di(tert-butyl)-5-hydroxyphenyl]-4-oxo-1H,4H-quinoline-3-carboxamide
- Vx-770